TP53 and mantle cell lymphoma: Using a threshold of 4% VAF as in the validation study [13], at least one somatic mutation was detected in 143/180 (79%) patients, in 88/117 (75%) patients of the MCL Younger and 55/63 (87%) patients of the MCL Elderly cohort, mostly in genes described as driver mutations in MCL such as ATM (35%), TP53 (24%), KMT2D (22%), SAMHD1 (10%), BIRC3 and NFKBIE (5%) (Fig. 2A, Table 3).